Stockholders’ Equity (Tables)
|
3 Months Ended |
Mar. 31, 2022 |
|---|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| Schedule of Share Based Payments Award Stock Options Valuation Assumptions |
Schedule
of Share Based Payments Award Stock Options Valuation Assumptions
Assumptions:
| |
|
2022 |
|
|
2021 |
|
| Dividend
yield |
|
|
0.00 |
% |
|
|
0.00 |
% |
| Risk-free
interest rate |
|
|
0.95-1.65 |
% |
|
|
0.19-0.67 |
% |
| Expected
volatility |
|
|
106.4-110.0
|
% |
|
|
117.0–124.0 |
% |
| Expected
life (in years) |
|
|
5 |
|
|
|
5 |
|
|
| Schedule of Stock Option Activity |
Option
activity for the three months ended March 31, 2022 and the year ended December 31, 2021 was as follows:
Schedule
of Stock Option Activity
| |
|
Options |
|
|
Weighted Average Exercise Price ($) |
|
|
Weighted Average Remaining Contractual Life (Yrs.) |
|
|
Aggregate Intrinsic Value ($) |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding at December 31, 2020 |
|
|
713,010 |
|
|
|
5.15 |
|
|
|
4.40 |
|
|
|
477,802 |
|
| Granted |
|
|
698,831 |
|
|
|
3.29 |
|
|
|
4.39 |
|
|
|
46,800 |
|
| Exercised |
|
|
(5,204 |
) |
|
|
2.50 |
|
|
|
- |
|
|
|
- |
|
| Forfeited or cancelled |
|
|
(10,755 |
) |
|
|
3.49 |
|
|
|
- |
|
|
|
- |
|
| Options outstanding at December 31, 2021 |
|
|
1,395,882 |
|
|
|
4.24 |
|
|
|
3.89 |
|
|
|
- |
|
| Granted |
|
|
162,000 |
|
|
|
2.50 |
|
|
|
4.94 |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Forfeited or cancelled |
|
|
(10,085 |
) |
|
|
3.60 |
|
|
|
- |
|
|
|
- |
|
| Options outstanding March 31, 2022 |
|
|
1,547,797 |
|
|
|
4.06 |
|
|
|
3.78 |
|
|
|
- |
|
| Options expected to vest in the future as of March 31, 2022 |
|
|
526,617 |
|
|
|
3.29 |
|
|
|
4.12 |
|
|
|
- |
|
| Options exercisable at March 31, 2022 |
|
|
1,021,180 |
|
|
|
4.46 |
|
|
|
3.60 |
|
|
|
- |
|
| Options vested, exercisable, and options expected to vest at March 31, 2022 |
|
|
1,547,797 |
|
|
|
4.06 |
|
|
|
3.78 |
|
|
|
- |
|
|
| Schedule of Warranty Activity |
Warrant
activity for the three months ended March 31, 2022 the year ended December 31, 2021 was as follows:
Schedule
of Warranty Activity
| |
|
Warrants |
|
|
Weighted Average Exercise Price ($) |
|
|
Weighted Average Remaining Contractual Life (Yrs.) |
|
| Warrants outstanding at December 31, 2020 |
|
|
1,881,429 |
|
|
|
7.57 |
|
|
|
4.16 |
|
| Granted |
|
|
2,602,143 |
|
|
|
4.36 |
|
|
|
1.63 |
|
| Exercised |
|
|
(495,641 |
) |
|
|
- |
|
|
|
- |
|
| Forfeited or cancelled |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Warrants outstanding at December 31, 2021 |
|
|
3,987,931 |
|
|
|
6.10 |
|
|
|
2.10 |
|
| Granted |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Forfeited or cancelled |
|
|
(162,150 |
) |
|
|
40.00 |
|
|
|
- |
|
| Warrants outstanding at March 31, 2022 |
|
|
3,825,781 |
|
|
|
4.66 |
|
|
|
1.94 |
|
|
| Stock Appreciation Rights [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| Schedule of Share Based Payments Award Stock Options Valuation Assumptions |
The
fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the three months
ended March 31, 2022 and the year ended December 31, 2021:
Schedule
of Share Based Payments Award Stock Options Valuation Assumptions
Assumptions:
| |
|
2022 |
|
|
2021 |
|
| Dividend
yield |
|
|
0.00 |
% |
|
|
0.00 |
% |
| Risk-free
interest rate |
|
|
0.82-1.65
|
%
|
|
|
0.39-0.40
|
%
|
| Expected
volatility |
|
|
108.4%-119.0
|
% |
|
|
123.0 |
% |
| Expected
life (in years) |
|
|
5 |
|
|
|
5 |
|
|
| Schedule of Stock Option Activity |
SARs
activity for the three months ended March 31, 2022 and the year ended December 31, 2021 was as follows:
Schedule
of Stock Option Activity
| |
|
Options |
|
|
Weighted
Average Exercise Price ($) |
|
|
Weighted
Average Remaining Contractual Life (Yrs.) |
|
|
Aggregate
Intrinsic Value ($) |
|
| |
|
|
|
|
|
|
|
- |
|
|
|
|
| SARs
outstanding at December 31, 2020 |
|
|
127,679 |
|
|
|
2.61 |
|
|
|
4.52 |
|
|
|
97,919 |
|
| Granted |
|
|
242,945 |
|
|
|
3.43 |
|
|
|
4.61 |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Forfeited
or cancelled |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
| SARs
outstanding at December 31, 2021 |
|
|
370,624 |
|
|
|
3.15 |
|
|
|
4.24 |
|
|
|
- |
|
| Granted |
|
|
45,033 |
|
|
|
2.33 |
|
|
|
4.86 |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Forfeited
or cancelled |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| SARs
outstanding March 31, 2022 |
|
|
415,657 |
|
|
|
3.06 |
|
|
|
4.08 |
|
|
|
2,046 |
|
| SARs
expected to vest in the future as of March 31, 2022 |
|
|
339,732 |
|
|
|
3.16 |
|
|
|
4.16 |
|
|
|
- |
|
| SARs
exercisable at March 31, 2022 |
|
|
75,925 |
|
|
|
2.63 |
|
|
|
3.74 |
|
|
|
2,046 |
|
| SARs
vested, exercisable, and SARs expected to vest at March 31, 2022 |
|
|
415,657 |
|
|
|
3.06 |
|
|
|
1.08 |
|
|
|
2,046 |
|
|